Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.48 |
| ▸ | AOC1 | P19801 | 5/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31407203 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4AOC1AOC3CYP2A6 | |
| SCHEMBL31407243 | 0.78 | SLC6A2 (0.49) | SLC6A2SLC6A4AOC1AOC3CYP2A6 | |
| SCHEMBL31407254 | 0.78 | LOXL2 (0.57) | SLC6A2SLC6A4AOC1AOC3CYP2A6 | |
| SCHEMBL22961934 | 0.78 | AOC1 (0.43) | SLC6A2SLC6A4AOC1AOC3CYP2A6 | |
| SCHEMBL12836473 | 0.78 | SLC6A2 (0.54) | SLC6A2SLC6A4AOC1AOC3CYP2A6 | |
| SCHEMBL16547439 | 0.78 | SLC6A2 (0.54) | SLC6A2SLC6A4AOC1AOC3CYP2A6 | |
| SCHEMBL5768459 | 0.78 | SLC6A2 (0.51) | SLC6A2SLC6A4AOC1AOC3CYP2A6 | |
| SCHEMBL31407214 | 0.78 | SLC6A2 (0.49) | SLC6A2SLC6A4AOC1AOC3CYP2A6 | |
| SCHEMBL13732150 | 0.77 | ALDH1A1 (0.46) | HTTCYP2C9 | |
| Hydrochloric Acid SCHEMBL31407242 | 0.76 | SLC6A2 (0.50) | SLC6A2SLC6A4AOC1AOC3CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-8703776-B2 | Agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703776-B2 | Agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703776-B2 | Agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8470813-B2 | Thiazoline and oxazoline derivatives and their methods of use | ABBVIE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130059856-A1 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059856-A1 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059856-A1 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2012174164-A2 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174164-A2 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100190776-A1 | Thiazoline and Oxazoline Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-07-29 | — | — | US | disclosed |
| US-7727985-B2 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727985-B2 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100093713-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093713-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7683084-B2 | Thiazoline and oxazoline derivatives and their methods of use | ABBOTT LABORATORIES (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2038278-A2 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008002956-A2 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059856-A1 | AGONISTS OF GPR131 AND USES THEREOF | GPR119, GPR88, GPR27 | SLC6A2 1002/4885SLC6A4 920/4885AOC1 3586/4885 |
| US-20100093713-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | NFKBIA, NFKB2, IKBKG | SLC6A2 4720/4885SLC6A4 4696/4885AOC1 4685/4885 |
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | SLC6A2 2944/4885SLC6A4 3652/4885AOC1 3681/4885 |
| US-20100190776-A1 | Thiazoline and Oxazoline Derivatives and Their Methods of Use | OXA1L, CYP3A7, ABAT | SLC6A2 1549/4885SLC6A4 1015/4885AOC1 477/4885 |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | OXA1L, CYP3A7, ABAT | SLC6A2 1549/4885SLC6A4 1015/4885AOC1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.